Growth is easier to celebrate when the product driving it feels permanent.

Christian Stella learned what happens when it does not.

Stella, CEO and co-founder of Precision Medicine, entered pharmacy through a family business on Long Island. A fourth-generation pharmacist, he graduated from St. John’s University in 2017 and began working above his family’s traditional pharmacy in a roughly 500-square-foot space dedicated to compounded medications.

He describes those early days as the “garage band of pharmacy.”

The business eventually became something far larger. Precision Medicine developed technology integrations for telehealth companies, expanded its licensing footprint across most of the United States, and built facilities in New York and Florida, with another in California.

But one of the most consequential decisions Stella has made involved deciding what the company would stop producing.

A Revenue Surge Can Hide a Strategic Risk

Compounding pharmacies prepare medications for specific patient needs and, under certain circumstances, can also produce versions of drugs that are commercially unavailable because of shortages.

That became especially important during the rapid rise of GLP-1 weight-loss medications.

As consumer demand surged and branded drugs experienced shortages, Stella says Precision Medicine began producing compounded GLP-1 medications within the rules that applied during that shortage period. At the same time, telehealth companies were expanding rapidly, creating an unusually powerful combination of demand, digital distribution, and constrained pharmaceutical supply.

For compounders, the opportunity was enormous.

Then the shortage environment changed.

Stella says Precision Medicine’s leadership team had to decide whether the revenue was worth the regulatory and legal uncertainty they believed could follow continued production once branded supply became more available.

The company stepped away.

That choice came with an immediate operational consequence. Precision Medicine reduced its workforce by roughly 100 employees as it resized the company around the remaining business.

For Stella, the decision was about the kind of company he wanted to build.

“We want to build something on concrete rather than sand,” he says.

Protecting the Business Can Mean Giving Up Revenue

Entrepreneurs are usually taught to pursue growing markets aggressively. Stella’s experience offers a complication to that advice.

A large revenue stream can still be a poor foundation if management believes the conditions supporting it may disappear.

Precision Medicine had other businesses in areas including hormone replacement, longevity-focused products, sexual health, and fulfillment services for telehealth companies. Stella and his team decided preserving those operations mattered more than maximizing short-term GLP-1 revenue.

The move required the company to absorb a painful transition rather than hope the market would remain favorable.

Stella says the outcome has been stronger than management initially projected. After the workforce reduction, the company expected revenue and profitability to fall much further than they ultimately did, while the remaining business returned to month-over-month growth.

That experience also sharpened Stella’s view of his role as CEO. He describes himself as a recovering people pleaser, a tendency that becomes difficult to sustain when leadership requires layoffs, capital decisions, regulatory judgment, and choices that disappoint people in the short term.

Growth Is Moving Toward New Forms, Not Just New Drugs

Precision Medicine’s next phase is centered partly on how medications are delivered.

Stella believes compounded medicine is becoming more consumer-oriented while remaining far more regulated than the supplement industry. That means differentiation may increasingly come from dosage formats, convenience, branding, and adherence rather than simply offering the same compound as competitors.

The company has invested in developing pectin-based gummy formulations, including specialized drying rooms, equipment, and food-science expertise. Stella also sees potential in peptides if additional compounds eventually become available for legitimate compounding under applicable regulatory frameworks.

The broader ambition is to make Precision Medicine a fulfillment infrastructure provider for modern healthcare, particularly for telehealth companies that want medications produced, branded, packaged, and shipped directly to patients.

That requires expansion, but Stella’s experience with GLP-1s has changed what kind of expansion he considers worthwhile.

The goal is no longer simply to follow the largest demand curve.

It is to identify revenue that can survive after the excitement, shortage, or regulatory window that created it has disappeared.

Want more From the Ground Up? Check out more articles or head over to YouTube, Apple, or Spotify to watch the videos.